Intravital imaging of glioma border morphology reveals distinctive cellular dynamics and contribution to tumor cell invasion.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 02 2019
Historique:
received: 24 07 2018
accepted: 18 12 2018
entrez: 16 2 2019
pubmed: 16 2 2019
medline: 30 9 2020
Statut: epublish

Résumé

The pathogenesis of glioblastoma (GBM) is characterized by highly invasive behavior allowing dissemination and progression. A conclusive image of the invasive process is not available. The aim of this work was to study invasion dynamics in GBM using an innovative in vivo imaging approach. Primary brain tumor initiating cell lines from IDH-wild type GBM stably expressing H2B-Dendra2 were implanted orthotopically in the brains of SCID mice. Using high-resolution time-lapse intravital imaging, tumor cell migration in the tumor core, border and invasive front was recorded. Tumor cell dynamics at different border configurations were analyzed and multivariate linear modelling of tumor cell spreading was performed. We found tumor border configurations, recapitulating human tumor border morphologies. Not only tumor borders but also the tumor core was composed of highly dynamic cells, with no clear correlation to the ability to spread into the brain. Two types of border configurations contributed to tumor cell spreading through distinct invasion patterns: an invasive margin that executes slow but directed invasion, and a diffuse infiltration margin with fast but less directed movement. By providing a more detailed view on glioma invasion patterns, our study may improve accuracy of prognosis and serve as a basis for personalized therapeutic approaches.

Identifiants

pubmed: 30765850
doi: 10.1038/s41598-019-38625-4
pii: 10.1038/s41598-019-38625-4
pmc: PMC6375955
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2054

Subventions

Organisme : European Research Council
ID : 648804
Pays : International

Références

Oncotarget. 2017 Jan 31;8(5):8250-8263
pubmed: 28030813
Cancer Discov. 2015 Sep;5(9):932-43
pubmed: 26269515
Nat Methods. 2018 Jan;15(1):73-80
pubmed: 29176592
J Vis Exp. 2017 Jul 20;(125):
pubmed: 28784966
Dev Biol. 2017 Aug 15;428(2):328-337
pubmed: 28473106
Acta Neuropathol. 2007 Nov;114(5):443-58
pubmed: 17805551
Tumori. 2015 Jul-Aug;101(4):390-7
pubmed: 26045126
Arch Neurol. 2012 Apr;69(4):523-6
pubmed: 22158715
PLoS One. 2014 Sep 30;9(9):e108632
pubmed: 25268354
Biochim Biophys Acta. 2014 Aug;1840(8):2386-95
pubmed: 24721714
Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69
pubmed: 15094120
J Cell Biol. 2016 Jan 18;212(2):143-55
pubmed: 26783298
Nat Rev Dis Primers. 2015 Jul 16;1:15017
pubmed: 27188790
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Nat Rev Cancer. 2015 Aug;15(8):499-509
pubmed: 26156637
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Neurosurg Focus. 2014 Dec;37(6):E6
pubmed: 25434391
Nat Cell Biol. 2007 Dec;9(12):1392-400
pubmed: 18037882
Exp Cell Res. 2016 Dec 10;349(2):199-213
pubmed: 27515001
Cell. 2013 Dec 19;155(7):1639-51
pubmed: 24332913
Biomaterials. 2013 Jul;34(21):5181-90
pubmed: 23601662
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Intravital. 2013 Apr 1;2(2):e25294
pubmed: 25013744
Nat Cell Biol. 2013 Apr;15(4):338-44
pubmed: 23548926
Cancer Cell. 2015 Sep 14;28(3):318-28
pubmed: 26373279
J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93
pubmed: 17971532
Cell. 2011 Nov 23;147(5):992-1009
pubmed: 22118458
Oncol Lett. 2016 Mar;11(3):1615-1620
pubmed: 26998052
J Neurooncol. 2004 Nov;70(2):217-28
pubmed: 15674479
Nat Rev Neurosci. 2014 Jul;15(7):455-65
pubmed: 24946761
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Neoplasia. 2005 Jan;7(1):7-16
pubmed: 15720813
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Nat Rev Cancer. 2016 Jan;16(1):56-66
pubmed: 26694936
Cancer Res. 2011 Jul 1;71(13):4608-16
pubmed: 21712408
Histochem Cell Biol. 2017 Oct;148(4):395-406
pubmed: 28825130
Nat Biotechnol. 2006 Apr;24(4):461-5
pubmed: 16550175
Nature. 2015 Dec 3;528(7580):93-8
pubmed: 26536111
EMBO Rep. 2012 Nov 6;13(11):984-91
pubmed: 23059978
Nat Clin Pract Neurol. 2008 Aug;4(8):427-35
pubmed: 18628751
Curr Opin Genet Dev. 2005 Feb;15(1):87-96
pubmed: 15661538
PLoS One. 2014 Nov 03;9(11):e111783
pubmed: 25365423
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Clin Cancer Res. 2016 Dec 15;22(24):6078-6087
pubmed: 27521448
Nat Rev Cancer. 2006 Jun;6(6):425-36
pubmed: 16723989
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
Curr Biol. 2007 Oct 9;17(19):1623-34
pubmed: 17825562
Intravital. 2014 Aug 11;3(2):e29917
pubmed: 28243510
Sci Rep. 2017 Aug 8;7(1):7529
pubmed: 28790339
Oncotarget. 2016 Sep 27;7(39):62989-63002
pubmed: 27556305
Cell Rep. 2016 Mar 15;14(10):2281-8
pubmed: 26947068
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Adv Drug Deliv Rev. 2017 Apr;113:61-86
pubmed: 27266447
Annu Rev Pathol. 2006;1:97-117
pubmed: 18039109
Cell. 2015 May 21;161(5):1046-1057
pubmed: 26000481
Neuro Oncol. 2017 Oct 01;19(10):1316-1326
pubmed: 28419303
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
Nat Rev Neurosci. 2013 Oct;14(10):722-9
pubmed: 23985834
Glia. 2009 Sep;57(12):1306-15
pubmed: 19191326
Brain Pathol. 2009 Oct;19(4):573-85
pubmed: 18662234
Methods. 2005 Oct;37(2):208-15
pubmed: 16288884

Auteurs

Maria Alieva (M)

Hubrecht Institute-KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands. m.alieva@prinsesmaximacentrum.nl.
Prinses Máxima Center for Pediatric Oncology, Uppsalalaan 8, 3584CT, Utrecht, The Netherlands. m.alieva@prinsesmaximacentrum.nl.

Verena Leidgens (V)

Hubrecht Institute-KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.
Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany.

Markus J Riemenschneider (MJ)

Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany.

Christoph A Klein (CA)

Department of Experimental Medicine, University of Regensburg, Regensburg, Germany.

Peter Hau (P)

Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany. peter.hau@ukr.de.

Jacco van Rheenen (J)

Hubrecht Institute-KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.
Department of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH